| 朱世祥,阚海峰,曹海燕.非小细胞肺癌病人血清不规则趋化因子表达及与肿瘤负荷、微血管密度相关性研究[J].安徽医药,2023,27(12):2416-2420. |
| 非小细胞肺癌病人血清不规则趋化因子表达及与肿瘤负荷、微血管密度相关性研究 |
| Expression of serum irregular chemokines and their correlation with tumor burden and microvascular density in non-small cell lung cancer patients |
| |
| DOI：10.3969/j.issn.1009-6469.2023.12.018 |
| 中文关键词: 癌，非小细胞肺 不规则趋化因子 肿瘤负荷 微血管密度 |
| 英文关键词: Carcinoma, non-small-cell lung Fractalkine Tumor load Microvascular density |
| 基金项目:南通市社会民生科技计划 -指导项目( MSZ19141) |
|
| 摘要点击次数: 896 |
| 全文下载次数: 433 |
| 中文摘要: |
| 目的探讨非小细胞肺癌( NSCLC)病人血清不规则趋化因子( fractalkine)表达及与肿瘤负荷、微血管密度( MVD)相关性。方法按照 1∶1∶1分别选取如皋市人民医院 2020年 9月至 2022年 5月标准化差异法下年龄、性别、身体质量指数均衡可比的 69例 NSCLC病人( NSCLC组)、 69例肺部良性疾病病人(良性组)、体检中心 69例健康对照人群(对照组)，比较各组血清 fractalkine、胃泌素释放肽前体( Pro-GRP)、神经元特异性烯醇化酶( NSE)、细胞角蛋白片段 19(CYFRA21-1)、鳞状细胞癌抗原( SCC)水平，采用受试者操作特征( ROC)曲线分析血清 fractalkine诊断 NSCLC价值，比较不同血清 fractalkine水平病人肿瘤负荷原发灶最长径、全身肿瘤代谢体积( MTVwb)、全身病灶总糖酵解值( TLGwb)、 MVD，应用 Pearson分析血清 fractalkine与肿瘤负荷、 MVD关系，并比较 NSCLC组治疗前后血清 fractalkine水平。结果 NSCLC组血清 fractalkine(646.44±208.12)ng/L、 Pro-GRP(79.64±20.01)ng/L、NSE(34.52±11.71)μg/L、CYFRA21-1(4.87±1.29)μg/L、SCC(5.82±1.63)μg/L高于良性组［( 422.03± 153.59)ng/L、(30.99±8.74)ng/L、(14.38±4.52)μg/L、(1.90±0.53)μg/L、(1.45±0.37)μg/L］和对照组［( 363.90±47.26)ng/L、(28.75±9.02)ng/L、(13.92±4.74)μg/L、(1.86±0.48)μg/L、(1.37±0.35)μg/L］(P<0.05)，良性组血清 fractalkine高于对照组( P<0.05)；血清 fractalkine诊断 NSCLC的 AUC与 Pro-GRP、NSE、CYFRA21-1、SCC相近( P>0.05)；血清 Fractalkine高水平病人原发灶最长径、 MTVwb、TLGwb、MVD均高于低水平病人( P<0.05)；血清 fractalkine水平与原发灶最长径( r=0.72)、 MTVwb(r=0.73)、 TLGwb(r=0.82)、 MVD(r=0.76)呈正相关(均 P<0.05)； NSCLC组治疗后血清 fractalkine水平较治疗前显著降低( P<0.05)。结论 NSCLC病人血清 fractalkine升高，与病人肿瘤负荷、 MVD有关，可作为诊断、评估病情及疗效的标志物，并有望为 NSCLC治疗带来新的靶点与思路。 |
| 英文摘要: |
| Objective To explore serum irregular chemokine (fractalkine) expression and its correlation with tumor load and mi.crovessel density (MVD) in patients with non-small cell lung cancer (NSCLC).Methods Sixty-nine NSCLC patients (NSCLC group),69 benign lung disease patients (benign group), and 69 healthy control population (control group) from the physical examination center,who were treated or had checkup from September 2020 to May 2022, were selected in a ratio of 1∶1∶1 according to the standardizeddifference method of age, gender, and body mass index from Rugao People's Hospital. A comparison was made of the serum levels offractalkine, pro-gastrin-releasing peptide (pro-GRP), neuron-specific enolase (NSE), cytokeratin19fragmentantigen21-1 (CYFRA21-1),and squamous cell carcinoma antigen (SCC) in each group, and the diagnostic value of serum fractalkine in NSCLC was analyzed usingthe receiver operating characteristic (ROC) curve. The maximum diameter of the primary tumor foci, total tumor metabolic volume (MT.Vwb), total glycolysis value (TLGwb), and MVD of patients with different serum fractalkine levels were compared. Pearson analysis wasused to analyze the relationship between serum fractalkine and tumor burden as well as MVD, and to compare the serum fractalkine lev.els before and after treatment in the NSCLC group.Results The serum fractalkine levels, pro-GRP, NSE, CYFRA21-1, and SCC in theNSCLC group were (646.44±208.12) ng/L, (79.64±20.01) ng/L, (34.52±11.71) μg/L, (4.87±1.29) μg/L, and (5.82±1.63)μg/L, respec.tively, which were higher than those in the benign group [(422.03±153.59) ng/L, (30.99±8.74) ng/L, (14.38±4.52) μg/L, (1.90±0.53) μg/L, (1.45±0.37)μg/L] and the control group [(363.90±47.26) ng/L, (28.75±9.02) ng/L, (13.92±4.74) μg/L, (1.86±0.48) μg/L, (1.37±0.35)μg/L] (P<0.05), and serum fractalkine was higher in the benign group than in the control group (P<0.05). The AUC of serum fractalkine for the diagnosis of NSCLC was similar to that of Pro-GRP, NSE, CYFRA21-1, and SCC (P>0.05). The maximum diameter of primary fo.ci, MTVwb, TLGwb, and MVD were higher in patients with high level of serum fractalkine than in those with low level (P<0.05). Serum fractalkine levels were positively associated with the maximum diameter of primary foci (r=0.72), MTVwb (r=0.73), TLGwb (r=0.82), and MVD (r=0.76) (all P<0.05). Serum fractalkine levels were significantly lower in the NSCLC group after treatment, as compared with those before treatment (P<0.05). Conclusion Elevated serum fractalkine in NSCLC patients is associated with patients' tumor loadand MVD, which can be used as a marker for diagnosis, assessment and efficacy of disease, and is expected to bring new targets andideas for NSCLC treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
